Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma

详细信息    查看全文

• 作者：Shan-Shan Jiang (1)
  De-Sheng Weng (1)
  Qi-Jing Wang (1)
  Ke Pan (1)
  Yao-Jun Zhang (1) (2)
  Yong-Qiang Li (1)
  Jian-Jun Li (1)
  Jing-Jing Zhao (1)
  Jia He (1)
  Lin Lv (1)
  Qiu-Zhong Pan (1)
  Jian-Chuan Xia (1)
  
  1. State Key Laboratory of Oncology in Southern China and Department of Experimental Research ; Sun Yat-sen University Cancer Center ; 651 Dongfeng Road East ; Guangzhou ; 510060 ; PR China
  2. Department of Hepatobiliary Oncology ; Sun Yat-sen University Cancer Center ; Guangzhou ; People鈥檚 Republic of China
  
• 关键词：Galectin ; 3 ; Hepatocellular carcinoma ; Angiogenesis ; Apoptosis ; Prognostic factor
• 刊名：Journal of Translational Medicine
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：12
• 期：1
• 全文大小：3,484 KB
• 参考文献：1. Murray, CJ, Lopez, AD (1997) Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349: pp. 1269-1276 le="It opens in new window">CrossRef
  2. Thomas, MB, Zhu, AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23: pp. 2892-2899 le="It opens in new window">CrossRef
  3. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90 le="It opens in new window">CrossRef
  4. Bosch, FX, Ribes, J, Borras, J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19: pp. 271-285 le="It opens in new window">CrossRef
  5. Hu, TH, Huang, CC, Lin, PR, Chang, HW, Ger, LP, Lin, YW, Chang Chien, CS, Lee, CM, Tai, MH (2003) Expression and prognostic role of tumor suppressor gene PTEN/MMA C1/TEP1 in hepatocellular carcinoma. Cancer 97: pp. 1929-1940 le="It opens in new window">CrossRef
  6. Wang, J, An, H, Mayo, MW, Baldwin, AS, Yarbrough, WG (2007) LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 12: pp. 239-251 le="It opens in new window">CrossRef
  7. Stebbing, J, Filipovic, A, Giamas, G (2013) Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene 32: pp. 4871-4872 le="It opens in new window">CrossRef
  8. Boscher, C, Zheng, YZ, Lakshminarayan, R, Johannes, L, Dennis, JW, Foster, LJ, Nabi, IR (2012) Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem 287: pp. 32940-32952 le="It opens in new window">CrossRef
  9. Friedrichs, J, Torkko, JM, Helenius, J, Teravainen, TP, Fullekrug, J, Muller, DJ, Simons, K, Manninen, A (2007) Contributions of galectin-3 and 鈭? to epithelial cell adhesion analyzed by single cell force spectroscopy. J Biol Chem 282: pp. 29375-29383 le="It opens in new window">CrossRef
  10. Barondes, SH, Cooper, DN, Gitt, MA, Galectins, LH (1994) Structure and function of a large family of animal lectins. J Biol Chem 269: pp. 20807-20810
  11. Gong, HC, Honjo, Y, Nangia-Makker, P, Hogan, V, Mazurak, N, Bresalier, RS, Raz, A (1999) The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59: pp. 6239-6245
  12. Nakahara, S, Oka, N, Raz, A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10: pp. 267-275 le="It opens in new window">CrossRef
  13. Ochieng, J, Furtak, V, Lukyanov, P (2004) Extracellular functions of galectin-3. Glycoconj J 19: pp. 527-535 le="It opens in new window">CrossRef
  14. Patterson, RJ, Wang, W, Wang, JL (2004) Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj J 19: pp. 499-506 le="It opens in new window">CrossRef
  15. Blanquart, C, Gueugnon, F, Nguyen, JM, Roulois, D, Cellerin, L, Sagan, C, Perigaud, C, Scherpereel, A, Gregoire, M (2012) CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol 7: pp. 883-889 le="It opens in new window">CrossRef
  16. Mayoral, MA, Mayoral, C, Meneses, A, IVillalvazo, L, Guzman, A, Espinosa, B, Ochoa, JL, Zenteno, E, Guevara, J (2008) Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Invest 26: pp. 615-623 le="It opens in new window">CrossRef
  17. Okada, K, Shimura, T, Suehiro, T, Mochiki, E, Kuwano, H (2006) Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 26: pp. 1369-1376
  18. Tsuboi, K, Shimura, T, Masuda, N, Ide, M, Tsutsumi, S, Yamaguchi, S, Asao, T, Kuwano, H (2007) Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 27: pp. 2289-2296
  19. Matsuda, Y, Yamagiwa, Y, Fukushima, K, Ueno, Y, Shimosegawa, T (2008) Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 38: pp. 1098-1111 le="It opens in new window">CrossRef
  20. Eude-Le Parco, I, Gendronneau, G, Dang, T, Delacour, D, Thijssen, VL, Edelmann, W, Peuchmaur, M, Poirier, F (2009) Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 19: pp. 68-75 le="It opens in new window">CrossRef
  21. Deutscher, SL, Figueroa, SD, Kumar, SR (2009) Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol 36: pp. 137-146 le="It opens in new window">CrossRef
  22. Chiu, CG, Strugnell, SS, Griffith, OL, Jones, SJ, Gown, AM, Walker, B, Nabi, IR, Wiseman, SM (2010) Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176: pp. 2067-2081 le="It opens in new window">CrossRef
  23. Hsu, DK, Dowling, CA, Jeng, KC, Chen, JT, Yang, RY, Liu, FT (1999) Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81: pp. 519-526 le="It opens in new window">CrossRef
  24. Peng, W, Wang, HY, Miyahara, Y, Peng, G, Wang, RF (2008) Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68: pp. 7228-7236 le="It opens in new window">CrossRef
  25. Zubieta, MR, Furman, D, Barrio, M, Bravo, AI, Domenichini, E, Mordoh, J (2006) Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168: pp. 1666-1675 le="It opens in new window">CrossRef
  26. Prieto, VG, Mourad-Zeidan, AA, Melnikova, V, Johnson, MM, Lopez, A, Diwan, AH, Lazar, AJ, Shen, SS, Zhang, PS, Reed, JA, Gershenwald, JE, Raz, A, Bar-Eli, M (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12: pp. 6709-6715 le="It opens in new window">CrossRef
  27. Honjo, Y, Nangia-Makker, P, Inohara, H, Raz, A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7: pp. 661-668
  28. Shimamura, T, Sakamoto, M, Ino, Y, Shimamura, T, Sakamoto, M, Ino, Y, Shimada, K, Kosuge, T, Sato, Y, Tanaka, K, Sekihara, H, Hirohashi, S (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8: pp. 2570-2575
  29. Cheng, CL, Hou, HA, Lee, MC, Liu, CY, Jhuang, JY, Lai, YJ, Lin, CW, Chen, HY, Liu, FT, Chou, WC, Chen, CY, Tang, JL, Yao, M, Huang, SY, Ko, BS, Wu, SJ, Tsay, W, Tien, HF (2013) Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 121: pp. 3172-3180 le="It opens in new window">CrossRef
  30. Piccolo, E, Tinari, N, Semeraro, D, Traini, S, Fichera, I, Cumashi, A, La Sorda, R, Spinella, F, Bagnato, A, Lattanzio, R, D鈥橢gidio, M, Risio, A, Stampolidis, P, Piantelli, M, Natoli, C, Ullrich, A, Iacobelli, S (2013) LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl) 91: pp. 83-94 le="It opens in new window">CrossRef
  31. Chen, C, Duckworth, CA, Zhao, Q, Pritchard, DM, Rhodes, JM, Yu, LG (2013) Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res 19: pp. 1693-1704 le="It opens in new window">CrossRef
  32. Kim, SJ, Shin, JY, Lee, KD, Bae, YK, Choi, IJ, Park, SH, Chun, KH (2011) Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 6: pp. e25103 le="It opens in new window">CrossRef
  33. Braeuer, RR, Zigler, M, Kamiya, T, Dobroff, AS, Huang, L, Choi, W, McConkey, DJ, Shoshan, E, Mobley, AK, Song, R, Raz, A, Bar-Eli, M (2012) Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 72: pp. 5757-5766 le="It opens in new window">CrossRef
  34. Wang, Y, Balan, V, Kho, D, Hogan, V, Nangia-Makker, P, Raz, A (2013) Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 32: pp. 5058-5065 le="It opens in new window">CrossRef
  35. Lee, YK1, Lin, TH, Chang, CF, Lo, YL (2013) Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via 尾-catenin/GSK-3尾 modulation in colorectal carcinoma. PLoS One 8: pp. e82478 le="It opens in new window">CrossRef
  36. Margadant, C, Bout, I, Boxtel, AL, Thijssen, VL, Sonnenberg, A (2012) Epigenetic regulation of galectin-3 expression by beta1 integrins promotes cell adhesion and migration. J Biol Chem 287: pp. 44684-44693 le="It opens in new window">CrossRef
  37. Zhang, D, Chen, ZG, Liu, SH, Dong, ZQ, Dalin, M, Bao, SS, Hu, YW, Wei, FC (2013) Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating beta-catenin. Acta Pharmacol Sin 34: pp. 176-184 le="It opens in new window">CrossRef
  
• 刊物主题：Biomedicine general; Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1479-5876

文摘

Background Galectin-3, a member of the beta-galactoside-binding lectin family, is a multifunctional protein with various biological functions, including the proliferation and differentiation of tumor cells, angiogenesis, cancer progression, and metastasis. We aimed to clarify if expression of galectin-3 is related to the clinicopathological characteristics and prognosis of hepatocellular carcinoma (HCC) patients, and to explore the possible mechanisms of galectin-3 in hepatocellular carcinoma. Methods First, we investigated galectin-3 mRNA and protein expression by using RT-PCR and Western blotting. Second, tissues from 165 HCC patients were used to evaluate clinicopathological characteristics and prognosis through immunohistochemical analyses. Furthermore, the functions of galectin-3 were analyzed with respect to the proliferation, cell cycle,apoptosis, migration, and invasion of HCC cell lines. Finally, we analyzed galectin-3 expression and micro-vessel density (MVD) by immunohistochemistry (IHC) to find its correlation with angiogenesis in Hepatocellular Carcinoma. Flow cytometer was used to explore apoptosis and Western-blot was used to detect the pathway proteins of apoptosis. Results Galectin-3 showed high expression at the mRNA and protein levels in HCC cancer tissues and cell lines. Clinicopathological analyses revealed that increased expression of galectin-3 in tumors was closely associated with a poor prognosis. Galectin-3 knockdown by siRNA significantly inhibited cell growth, migration, and invasion, and induced apoptosis in HCC cells in vitro, whereas galectin-3 overexpression promoted cell growth, migration, and invasion. Correlation analysis of galectin-3 expression and micro-vessel density (MVD) showed that galectin-3 expression in tumor cells stimulates angiogenesis. The observed regulation of cell apoptosis was accompanied by the galectin-3-mediated modulation of caspase3 signaling pathways in HCC cells. Conclusions These data suggest that galectin-3 plays an important part in HCC progression and may serve as a prognostic factor for HCC.